Abstract
We report the case of a 52-yr-old man with metastatic lung adenocarcinoma who developed tumor lysis syndrome after administration of zoledronic acid. Tumor lysis syndrome in solid tumors and the antitumor effect of the zolendronic acid are discussed in light of the pertinent literature.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kalemkerian GP, Darwish B, Varterasian ML. Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med 1997;103:363–367.
Bilgrami SF, Fallon BG. Tumor lysis syndrome after combination chemotherapy for ovarian cancer. Med Pediatr Oncol 1993;21:521–524.
Woo IS, et al. Spontaneous acute tumor lysis syndrome with advanced gastric cancer. J Korean Med Sci 2001;16:115–118.
Feld J, Mehta H, Burkes RL. Acute spontaneous tumor lysis syndrome in adenocarcinoma of the lung: a case report. Am J Clin Oncol 2000;23:491–493.
Baeksgaard L, Sorensen JB. Acute tumor lysis syndrome in solid tumors—a case report and review of the literature. Cancer Chemother Pharmacol 2003;51:187–192.
Vaisban E, Braester A, Mosenzon O, Kolin M, Horn Y. Spontaneous tumor lysis syndrome in solid tumors: really a rare condition? Am J Med Sci 2003;325:38–40.
Sklarin NT, Markham M. Spontaneous recurrent tumor lysis syndrome in breast cancer. Am J Clin Oncol 1995;18:71–73.
Beriwal S, Singh S, Garcia-Young JA. Tumor lysis syndrome in extensive-stage small-cell lung cancer. Am J Clin Oncol 2002;25:474–475.
Sewani HH, Rabatin JT. Acute tumor lysis syndrome in a patient with mixed small cell and non-small cell tumor. Mayo Clin Proc 2002;77:722–728.
Kallab AM, Jillella AP. Tumor lysis syndrome in small cell lung cancer. Med Oncol 2001;18:149–151.
Rosen LS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613–2621.
Green JR. Preclinical pharmacology of zoledronic acid. Semin Oncol 2002;29(6 Suppl. 21): 3–11.
Kimura S, et al. Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. Int J Hematol 2004;79:37–43.
Ural AU, et al. The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide. Int J Hematol 2003;78:443–449.
Tassone P, et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 2000;14:841–844.
Coxon JP, Oades GM, Kirby RS, Colston KW. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 2004;94:164–170.
Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000;15:2211–2221.
Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000;82:1459–1468.
Tassone P, et al. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 2003;88:1971–1978.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kurt, M., Onal, I.K., Elkiran, T. et al. Acute tumor lysis syndrome triggered by zoledronic acid in a patient with metastatic lung adenocarcinoma. Med Oncol 22, 203–206 (2005). https://doi.org/10.1385/MO:22:2:203
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/MO:22:2:203